Results of a phase II multicenter study of obinutuzumab plus bendamustine in pts with previously untreated chronic lymphocytic leukemia (CLL)

MLA

Nicholas J. DiBella, et al. “Results of a Phase II Multicenter Study of Obinutuzumab plus Bendamustine in Pts with Previously Untreated Chronic Lymphocytic Leukemia (CLL).” Journal of Clinical Oncology, vol. 35, May 2017, p. 7523. EBSCOhost, https://doi.org/10.1200/jco.2017.35.15_suppl.7523.

APA

Nicholas J. DiBella, Sandra Skettino, Habte A. Yimer, Sunil Babu, Alexey V. Danilov, Jia Li, Jeff Porter Sharman, Michael Boxer, & Yong Jun Mun. (2017). Results of a phase II multicenter study of obinutuzumab plus bendamustine in pts with previously untreated chronic lymphocytic leukemia (CLL). Journal of Clinical Oncology, 35, 7523. https://doi.org/10.1200/jco.2017.35.15_suppl.7523

Chicago

Nicholas J. DiBella, Sandra Skettino, Habte A. Yimer, Sunil Babu, Alexey V. Danilov, Jia Li, Jeff Porter Sharman, Michael Boxer, and Yong Jun Mun. 2017. “Results of a Phase II Multicenter Study of Obinutuzumab plus Bendamustine in Pts with Previously Untreated Chronic Lymphocytic Leukemia (CLL).” Journal of Clinical Oncology 35 (May): 7523. doi:10.1200/jco.2017.35.15_suppl.7523.